Related Experiment Video
Updated: Mar 1, 2026

03:25
Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
8.2K
Stability, Accuracy, and Risk Assessment of a Novel Subcutaneous Glucose Sensor
Jonathan Hughes1, John B Welsh1, Naresh C Bhavaraju1
11 Dexcom, Inc. , San Diego, California.
Diabetes Technology & Therapeutics
|June 7, 2017
Summary
This new continuous glucose monitoring (CGM) system demonstrates high accuracy and reliability over 10 days, with minimal risk of errors. Its ease of use supports its use in diabetes management.
Area of Science:
- Biomedical Engineering
- Medical Devices
- Diabetes Technology
Background:
- Continuous glucose monitoring (CGM) users face challenges with sensor insertion frequency, calibration, accuracy, and reliability.
- Concerns exist regarding the risks associated with inaccurate glucose readings from CGM systems.
Purpose of the Study:
- To evaluate the accuracy and reliability of a next-generation CGM system over a 10-day wear period.
- To assess the risk of discrepancies between CGM and self-monitored blood glucose (SMBG) values.
Main Methods:
- A 10-day accuracy study comparing a new CGM system with SMBG in 50 participants with diabetes.
- Daily sensor calibration and multiple daily SMBG measurements for comparison.
- Analysis of 2739 paired CGM-SMBG values and Surveillance Error Grid (SEG) analysis.
Main Results:
- The overall median Absolute Relative Difference (ARD) was 7.2%, decreasing from 8.9% on Day 1 to 6.5% on Day 10.
- 99.6% of measurements fell into the
- no
- or
- slight
- risk zones on the SEG.
- 79.6% of sensors functioned reliably for the full 10 days, with good sensor and adhesive tolerability.
Conclusions:
- The new CGM system exhibits high accuracy and reliability over its 10-day lifespan.
- Once-daily calibration offers convenience for users.
- The low risk of measurement errors supports its use in nonadjunctive diabetes management and automated insulin delivery systems.
Related Concept Videos
Hypoglycemia and Glucagon
1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
Glucose Homeostasis: Regulation of Blood Glucose
4.7K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
4.7K
Oral Hypoglycemic Agents: Glinides
760
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
760

